Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.55)
# 1,014
Out of 5,022 analysts
336
Total ratings
44.2%
Success rate
13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALDX Aldeyra Therapeutics | Reiterated: Hold | $2 | $1.17 | +70.94% | 34 | Sep 30, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $28.30 | +55.50% | 18 | Sep 30, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $58 → $96 | $94.45 | +1.64% | 18 | Sep 29, 2026 | |
| SRZN Surrozen | Reiterated: Buy | $44 → $54 | $29.32 | +84.17% | 11 | Sep 25, 2026 | |
| DMAC DiaMedica Therapeutics | Reiterated: Buy | $12 | $8.23 | +45.81% | 14 | Sep 21, 2026 | |
| PHAT Phathom Pharmaceuticals | Reiterated: Buy | $26 | $6.92 | +275.72% | 22 | Sep 21, 2026 | |
| IMUX Immunic | Reiterated: Buy | $22 | $7.96 | +176.38% | 17 | Sep 10, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 | $4.58 | +74.67% | 37 | Sep 8, 2026 | |
| UPB Upstream Bio | Reiterated: Buy | $36 | $5.04 | +614.29% | 3 | Sep 2, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $36 | $13.67 | +163.35% | 34 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $3.58 | +961.45% | 18 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 | $23.63 | +136.99% | 20 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.34 | +438.92% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $73.00 | +20.55% | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.865 | +593.64% | 13 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $6 | $1.24 | +383.87% | 13 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0234 | n/a | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.73 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $7.43 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $64.51 | n/a | 5 | Oct 21, 2022 |
Aldeyra Therapeutics
Sep 30, 2026
Reiterated: Hold
Price Target: $2
Current: $1.17
Upside: +70.94%
Zenas BioPharma
Sep 30, 2026
Reiterated: Buy
Price Target: $44
Current: $28.30
Upside: +55.50%
Kodiak Sciences
Sep 29, 2026
Reiterated: Buy
Price Target: $58 → $96
Current: $94.45
Upside: +1.64%
Surrozen
Sep 25, 2026
Reiterated: Buy
Price Target: $44 → $54
Current: $29.32
Upside: +84.17%
DiaMedica Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $12
Current: $8.23
Upside: +45.81%
Phathom Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: $26
Current: $6.92
Upside: +275.72%
Immunic
Sep 10, 2026
Reiterated: Buy
Price Target: $22
Current: $7.96
Upside: +176.38%
Opus Genetics
Sep 8, 2026
Reiterated: Buy
Price Target: $8
Current: $4.58
Upside: +74.67%
Upstream Bio
Sep 2, 2026
Reiterated: Buy
Price Target: $36
Current: $5.04
Upside: +614.29%
4D Molecular Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $36
Current: $13.67
Upside: +163.35%
Aug 12, 2026
Reiterated: Buy
Price Target: $38
Current: $3.58
Upside: +961.45%
Aug 12, 2026
Reiterated: Buy
Price Target: $56
Current: $23.63
Upside: +136.99%
Aug 7, 2026
Reiterated: Buy
Price Target: $18
Current: $3.34
Upside: +438.92%
Aug 7, 2026
Reiterated: Buy
Price Target: $88
Current: $73.00
Upside: +20.55%
Aug 6, 2026
Reiterated: Buy
Price Target: $6
Current: $0.865
Upside: +593.64%
Aug 4, 2026
Reiterated: Buy
Price Target: $8 → $6
Current: $1.24
Upside: +383.87%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.0234
Upside: n/a
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $3.73
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Reiterated: Buy
Price Target: $39
Current: $7.43
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $64.51
Upside: n/a